relapsed/refractory primary central nervous system lymphoma
Conditions
Interventions
experimental group:Zebutinib, rituximab, and lenalidomide combined regimen treatment
Sponsors
The Affiliated Hospital of Nantong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years; 2. Histopathologically diagnosed as non-GCB primary central nervous system lymphoma; 3. Patient received no less than one chemotherapy regimen, such as single agent HD-MTX or MTX combined treatments; 4. Disease progression proved by imagine examination 21 days before registration; 5. ECOG PS 0-2 points; 6. Patient fulfilled the following criteria 21 days before registration: neutrophils >=1.0 x 10^9/L or platelets >=75 x 10^9/L and hemoglobin >=8 g / dL without transfusion; total bilirubin <= 1.5 times of normal maximum, AST or ALT <= 3 times of normal maximum; INR or APTT <= 1.5 times of normal maximum; renal dysfunction with creatinine <= 2 times of normal maximum; 7.Women of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug. Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after last dose; 8. Willing to sign the written consent.
Exclusion criteria
Exclusion criteria: 1. The patient is using other approved or researched anti-tumor drugs at the same time; 2. Before starting the study drug, the patient has received chemotherapy, monoclonal antibody or targeted anti-cancer therapy for =5 mIU/mL; 18. The patient has received allogeneic stem cell transplantation (autologous stem cell transplantation is not excluded); 19. The patient is unwell or unable to participate in all necessary research evaluations and procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate;Adverse effects;Progression free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactShi Wenyu
The Affiliated Hospital of Nantong University
Outcome results
None listed